Related Experiment Videos
Does recombinant growth hormone improve adult height in children with chronic renal failure?
1Department of Pediatric Nephrology, Charité Hospital, Berlin, Germany. dieter.haffner@charite.de
Insights
Long-term recombinant human growth hormone (rhGH) treatment significantly improves adult height in children with chronic renal failure. Early and prolonged rhGH therapy is crucial for maximizing height benefits in these patients.
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Growth Hormone Therapy
Background:
- Chronic renal failure (CRF) in children often impairs growth and final adult height.
- Recombinant human growth hormone (rhGH) has been established as safe and effective for long-term treatment in children with CRF.
Purpose of the Study:
- To review the evidence for rhGH treatment improving adult height in patients with childhood-onset CRF.
- To identify factors influencing rhGH efficacy in this population.
Main Methods:
- Review of existing literature on rhGH treatment in pediatric CRF patients.
- Analysis of factors predicting height outcomes, including treatment duration and dialysis periods.
Main Results:
- rhGH treatment results in a significant improvement in adult height, averaging 1.0 to 1.5 standard deviations.
- Prepubertal rhGH treatment is more effective for final height than treatment during puberty.
- Cumulative duration of rhGH treatment positively predicts efficacy, while duration of dialysis negatively impacts it.
Conclusions:
- Prolonged rhGH treatment, initiated early in the course of CRF, is essential for achieving optimal adult height in children.
- The findings underscore the importance of early intervention with rhGH to mitigate growth deficits associated with chronic kidney disease.
Abstract:
During the past decade, the safety and efficacy of long-term treatment with recombinant human growth hormone (rhGH) in children with chronic renal failure before and after renal transplantation has been established. This article reviews the increasing evidence that rhGH treatment also results in a significant improvement of adult height in patients with childhood-onset chronic renal failure. The eventual height benefit of extended rhGH treatment appears to be 1.0 to 1.5 standard deviations on average. Whereas prepubertal rhGH treatment has a beneficial effect on final height, the efficacy of rhGH during puberty is less evident. The cumulative duration of rhGH treatment was found to be the most important positive, and the duration of dialysis treatment periods a negative predictor of rhGH efficacy, stressing the importance of prolonged rhGH treatment starting early in the course of chronic renal failure.